December 11, 2019 07:03 AM ESTUpdated December 12, 10:08 AM
R&D

Lit­tle Leo Phar­ma en­ters the prize-fight ring with pos­i­tive PhI­II atopic der­mati­tis da­ta. Now they just have to beat Dupix­ent

John Carroll

Editor & Founder

A day af­ter new Sanofi CEO Paul Hud­son staked his rep­u­ta­tion and the fu­ture of the phar­ma gi­ant on mak­ing Dupix­ent a mega­suc­cess sto­ry …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

A service from the Financial Times